Are Options Traders Betting on a Big Move in Zogenix (ZGNX) Stock?Zacks Investment Research • 06/20/20
Zogenix Launches Shine Forward with Dravet, a New Source of Inspiring Ideas for Parents of Children Living with Dravet SyndromeGlobeNewsWire • 05/15/20
Zogenix, Inc. (ZGNX) CEO Stephen Farr on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/06/20
Zogenix Appoints Shawnte Mitchell as Executive Vice President, General Counsel & SecretaryGlobeNewsWire • 04/20/20
Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 03/06/20
This Biotech Cratered On Its Good — But Not Good Enough — Test ResultsInvestors Business Daily • 02/07/20
The Lancet Publishes Phase 3 Trial Results for Zogenix Investigational Drug FINTEPLA® in Dravet SyndromeGlobeNewsWire • 12/18/19
JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug RegimensGlobeNewsWire • 12/02/19
Zogenix Inc's (ZGNX) CEO Steve Farr on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/08/19
Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA® in Dravet SyndromeGlobeNewsWire • 10/25/19